Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,161 to 1,180 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor. | Commun Biol | 2022 | 35233052 | PubTator, text mining | PubMed |
| Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay. | ACS Cent Sci | 2022 | 35229034 | PubTator, text mining | PubMed |
| Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? | J Virol | 2022 | 35225672 | PubTator, text mining | PubMed |
| COVID-19 can be called a treatable disease only after we have antivirals. | Sci Bull (Beijing) | 2022 | 35223129 | PubTator, text mining | PubMed |
| The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. | Front Microbiol | 2022 | 35222327 | PubTator, text mining | PubMed |
| PRRSV Non-Structural Proteins Orchestrate Porcine E3 Ubiquitin Ligase RNF122 to Promote PRRSV Proliferation. | Viruses | 2022 | 35216017 | PubTator, text mining | PubMed |
| In Silico Prediction and Selection of Target Sequences in the SARS-CoV-2 RNA Genome for an Antiviral Attack. | Viruses | 2022 | 35215977 | PubTator, text mining | PubMed |
| A Novel Motif in the 3'-UTR of PRRSV-2 Is Critical for Viral Multiplication and Contributes to Enhanced Replication Ability of Highly Pathogenic or L1 PRRSV. | Viruses | 2022 | 35215760 | PubTator, text mining | PubMed |
| Deciphering the Interactions of SARS-CoV-2 Proteins with Human Ion Channels Using Machine-Learning-Based Methods. | Pathogens | 2022 | 35215201 | PubTator, text mining | PubMed |
| Identification of intrinsically disorder regions in non-structural proteins of SARS-CoV-2: New insights into drug and vaccine resistance. | Mol Cell Biochem | 2022 | 35211823 | PubTator, text mining | PubMed |
| Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. | Int J Environ Res Public Health | 2022 | 35206580 | PubTator, text mining | PubMed |
| Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19. | Biomolecules | 2022 | 35204803 | PubTator, text mining | PubMed |
| Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? | Antibiotics (Basel) | 2022 | 35203821 | PubTator, text mining | PubMed |
| The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. | Signal Transduct Target Ther | 2022 | 35197452 | PubTator, text mining | PubMed |
| Genetic Engineering Systems to Study Human Viral Pathogens from the Coronaviridae Family. | Mol Biol | 2022 | 35194246 | PubTator, text mining | PubMed |
| In silico detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using molecular docking, molecular dynamic simulation and ADMET profiling. | J Mol Struct | 2022 | 35194243 | PubTator, text mining | PubMed |
| Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections. | Biotechnol Rep (Amst) | 2022 | 35186674 | PubTator, text mining | PubMed |
| [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. | Rev Esp Quimioter | 2022 | 35183067 | PubTator, text mining | PubMed |
| Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. | Bioorg Med Chem Lett | 2022 | 35182772 | PubTator, text mining | PubMed |
| Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors. | ACS Pharmacol Transl Sci | 2022 | 35178512 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=59